Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Stolte

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Brain Sciences|September 28, 2021
Cognitive Impairment in Adult Patients with 5q-Associated Spinal Muscular AtrophyKathrin Kizina, Yakup Akkaya, Daniel Jokisch, et al.
Neurological Research and Practice|December 16, 2020
Prevalence of hereditary transthyretin amyloid polyneuropathy in idiopathic progressive neuropathy in conurban areasAndreas Thimm, Saskia Bolz, Michael Fleischer, et al.
Human Gene Therapy|August 9, 2022
Prevalence of Anti-Adeno-Associated Virus Serotype 9 Antibodies in Adult Patients with Spinal Muscular AtrophyBenjamin Stolte, Olivia Schreiber-Katz, René Günther, et al.
Clinical Neuroradiology|March 4, 2022
Predictors of Early Neurological Improvement in Patients with Anterior Large Vessel Occlusion and Successful Reperfusion Following Endovascular Thrombectomy-Does CT Perfusion Imaging Matter?Yan Li, Natalie van Landeghem, Aydin Demircioglu, et al.
Brain Sciences|January 21, 2023
Health-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers-A Prospective, Cross-Sectional, Multi-Center AnalysisCamilla Wohnrade, Ann-Kathrin Velling, Lucas Mix, et al.
Therapeutic Advances in Neurological Disorders|March 22, 2021
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapyAlma Osmanovic, Gresa Ranxha, Mareike Kumpe, et al.
Annals of Clinical and Translational Neurology|April 1, 2021
Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatmentMaren Freigang, Claudia D Wurster, Tim Hagenacker, et al.
Annals of Clinical and Translational Neurology|February 22, 2022
Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophyCamilla Binz, Alma Osmanovic, Nele H Thomas, et al.
Therapeutic Advances in Neurological Disorders|March 19, 2021
Observational cohort study of neurological involvement among patients with SARS-CoV-2 infectionMichael Fleischer, Martin Köhrmann, Sebastian Dolff, et al.
European Journal of Neurology|May 7, 2021
Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersenThomas Meyer, André Maier, Zeljko Uzelac, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Brain Sciences|September 28, 2021
Cognitive Impairment in Adult Patients with 5q-Associated Spinal Muscular AtrophyKathrin Kizina, Yakup Akkaya, Daniel Jokisch, et al.
Neurological Research and Practice|December 16, 2020
Prevalence of hereditary transthyretin amyloid polyneuropathy in idiopathic progressive neuropathy in conurban areasAndreas Thimm, Saskia Bolz, Michael Fleischer, et al.
Human Gene Therapy|August 9, 2022
Prevalence of Anti-Adeno-Associated Virus Serotype 9 Antibodies in Adult Patients with Spinal Muscular AtrophyBenjamin Stolte, Olivia Schreiber-Katz, René Günther, et al.
Clinical Neuroradiology|March 4, 2022
Predictors of Early Neurological Improvement in Patients with Anterior Large Vessel Occlusion and Successful Reperfusion Following Endovascular Thrombectomy-Does CT Perfusion Imaging Matter?Yan Li, Natalie van Landeghem, Aydin Demircioglu, et al.
Brain Sciences|January 21, 2023
Health-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers-A Prospective, Cross-Sectional, Multi-Center AnalysisCamilla Wohnrade, Ann-Kathrin Velling, Lucas Mix, et al.
Therapeutic Advances in Neurological Disorders|March 22, 2021
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapyAlma Osmanovic, Gresa Ranxha, Mareike Kumpe, et al.
Annals of Clinical and Translational Neurology|April 1, 2021
Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatmentMaren Freigang, Claudia D Wurster, Tim Hagenacker, et al.
Annals of Clinical and Translational Neurology|February 22, 2022
Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophyCamilla Binz, Alma Osmanovic, Nele H Thomas, et al.
Therapeutic Advances in Neurological Disorders|March 19, 2021
Observational cohort study of neurological involvement among patients with SARS-CoV-2 infectionMichael Fleischer, Martin Köhrmann, Sebastian Dolff, et al.
European Journal of Neurology|May 7, 2021
Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersenThomas Meyer, André Maier, Zeljko Uzelac, et al.
Pageof 4